Andrew Grethlein - Geron Insider

GERN -- USA Stock  

USD 3.62  0.19  4.99%

Executive VP of Devel. and Technical Operations
Dr. Andrew J. Grethlein, Ph.D., is Executive Vice President Development and Technical Operations of Geron Corporationration Prior to that he served as our Executive Vice President, Technical Operations, since September 2012. Prior to joining Geron, Dr. Grethlein was Executive Vice President and Chief Operating Officer for Inspiration Biopharmaceuticals, a biopharmaceutical company, from January 2010 to September 2012. From October 2008 until January 2010, Dr. Grethlein was Senior Vice President of Biotechnology and Portfolio Management Team Leader for Hematology at Ipsen S.A., a global specialty pharmaceutical company. His responsibilities at Ipsen included planning and execution of worldwide strategy for product and portfolio development in the hematologic therapeutic area. From 2003 to 2008, Dr. Grethlein served as Senior Vice President of Pharmaceutical Operations at Tercica, Inc., an endocrinologyoriented biopharmaceutical company. In this role, he was a member of the senior executive team that governed corporate strategy, business planning and company operations, and had responsibility for all manufacturing and quality functions. Before joining Tercica, Dr. Grethlein served in various positions at Elan Corporationrationration, a biotechnology company, from 1997 to 2003, including as Senior Director, South San Francisco Pharmaceutical Operations, where he had responsibility as site head for commercial manufacturing operations. From 1995 to 1997, Dr. Grethlein served as Manager, Biologics Development and Manufacturing, for Athena Neurosciences, Inc., a pharmaceutical company. Prior to this, he served in various engineering positions for the Michigan Biotechnology Institute, a nonprofit technology research and business development corporation
Age: 49  EVP Since 2014      
Grethlein received his A.A. degree in liberal arts from Simon Rock Early College, his B.S. in biology from Bates College, and his M.S. and Ph.D. in chemical engineering from Michigan State University. .

Management Efficiency

The company has return on total asset (ROA) of (15.57) % which means that it has lost $15.57 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (25.57) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California. Geron operates under Biotechnology classification in USA and traded on NASDAQ. It employs 15 people.Geron Corporation (GERN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 15 people. Geron is listed under Pharmaceutical Products category by Fama And French industry classification.

Geron Leadership Team

Hoyoung Huh, Chairman, Ph.D
Kevin Eng, Executive
Daniel Bradbury, Director
John Scarlett, CEO
Melissa Behrs, President, MBA
Olivia Bloom, CFO
Robert Spiegel, Director, Ph.D
Andrew Grethlein, EVP
Karin Eastham, Director, MBA
Susan Molineaux, Director, Ph.D
Bryan Lawlis, Director, Ph.D
Stephen Rosenfield, President

Stock Performance Indicators

Did you try this?

Run Portfolio Manager Now

Portfolio Manager

State of the art Portfolio Manager to monitor and improve performance of your invested capital
All  Next Launch Portfolio Manager

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Equity Valuation module to check real value of public entities based on technical and fundamental data.